Pharmaceutical Preparations · LONDON, ENGLAND, X0, United Kingdom
$1.16
+5.45% (+$0.06)2026-06-18
Smart-Money SignalNeutral · 52/100— Insiders are net buyers over 90 days ($17K, 1 buy vs 0 sales)
Price Performance
Historical data including institutional events
Company Profile
I
Ivor Elrifi
CEO & Executive Director
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally.
It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimerâs disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
The company is headquartered in London, the United Kingdom.
